Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020

 Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020

Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020

Shots:

  • Novavax has identified a coronavirus vaccine candidate, NVX-CoV2373 utilizing its nanoparticle technology and will initiate a first-in-human trial in mid-May with its anticipated immunogenicity and safety results in July. Novavax will integrate its Matrix-M adjuvant with NVX-CoV2373 to improve the immune response stimulates high levels of neutralizing Ab
  • The company plans to combine P-I/II study, allowing the rapid advancement during a pandemic. The P-I clinical study will assess NVX-CoV2373 vs PBO in ~130 healthy adults and includes an assessment of dosage amount and the number of vaccinations
  • Earlier, the company collaborated with Emergent BioSolutions to provide GMP vaccine products for use in its clinical trials. Additionally, the CEPI has granted $4M to support Novavax’ efforts, with additional funding discussions ongoing

Click here ­to­ read full press release/ article | Ref: Novavax | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post